Gregg J. Silverman1*
Abhimanyu N. Amarnani1
Arnaldo A. Arbini2
Angie Kim3Hannah Kopinsky3David Fenyo4
Ilya Kister3- 1Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, NY, United States
- 2Department of Pathology, NYU Grossman School of Medicine, New York, NY, United States
- 3Department of Neurology, NYU Grossman School of Medicine, New York, NY, United States
- 4Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, United States
By Silverman GJ, Amarnani AN, Arbini AA, Kim A, Kopinsky H, Fenyo D and Kister I (2025) Front. Immunol. 16:1590165. doi: 10.3389/fimmu.2025.1590165
Author “Arnaldo A. Arbini” was erroneously spelled as “Arnaldo A. Armini”.
A correction has been made to the Abstract, first paragraph (Introduction)
Error:
“In this study, we explored the immunologic and genetic factors, with, serum drug monitoring that may contribute to a faster rate of B-cell repletion that follows during recovery from treatment with anti-CD20 antibody.”
Corrected sentence:
“In this study, we explored the immunologic and genetic factors, with serum drug monitoring, that may contribute to a faster rate of B-cell repletion that follows during recovery from treatment with anti-CD20 antibody.”
A correction has been made to the Introduction, first paragraph (after heading “1 Introduction”)
Error:
“Suspicion of the potential roles of B-cells in MS was first suggested based on oligoclonal immunoglobulin bands in the CSF of MS patients (4, 5) and later confirmed by on the clinical efficacy of B-cell-depleting therapies in suppressing relapses and new MRI lesions in MS (6, 7).”
Corrected sentence:
“Suspicion of the potential roles of B-cells in MS was first suggested based on oligoclonal immunoglobulin bands in the CSF of MS patients (4, 5) and later confirmed by the clinical efficacy of B-cell-depleting therapies in suppressing relapses and new MRI lesions in MS (6, 7).”
A correction has been made to the Materials and methods, Flow cytometric analyses (Section 2.3), second paragraph
Error:
“Cells were washed fixed, and data was acquired on a 5-laser (355/405/488/561/637 nm) SONY ID7000 Spectral analyzer.”
Corrected sentence:
“Cells were washed, fixed, and data were acquired on a 5-laser (355/405/488/561/637 nm) SONY ID7000 Spectral analyzer.”
A correction has been made to the Materials and methods, Statistical analyses of genetic SNP (Section 2.5), second paragraph
Error:
“Additionally, among the significantly overrepresented SNPs (Fisher’s exact test, p < 0.005) with a positive mean allele frequency in ERs compared to NRs, we identified 317 SNPs of interest that had a mean allele frequency of for NRs but an allele frequency of at least 2 in ERs (Supplementary Table S2).”
Corrected sentence:
“Additionally, among the significantly overrepresented SNPs (Fisher’s exact test, p < 0.005) with a positive mean allele frequency in ERs compared to NRs, we identified 317 SNPs of interest that had a mean allele frequency for NRs but an allele frequency of at least 2 in ERs (Supplementary Table S2).”
A correction has been made to the Discussion, fifth paragraph (after heading “4 Discussion”)
Error:
“In our patients, we observed an appropriate reciprocal decrease in serum BAFF levels concurrent with the period of peripheral B cell replenishment. In MS patients, the differences in BAFF levels in ER and NR thus appear to be a conseque”
Corrected sentence:
“In our patients, we observed an appropriate reciprocal decrease in serum BAFF levels concurrent with the period of peripheral B cell replenishment. In MS patients, the differences in BAFF levels in ER and NR thus appear to be a consequence.”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Ocrelizumab, multiple sclerosis, rituximab, CD20, African ancestry, B-cell repletion, genetics, B-cell activating factor
Citation: Silverman GJ, Amarnani AN, Arbini AA, Kim A, Kopinsky H, Fenyo D and Kister I (2025) Correction: B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with multiple sclerosis of African ancestry. Front. Immunol. 16:1649409. doi: 10.3389/fimmu.2025.1649409
Received: 18 June 2025; Accepted: 25 June 2025;
Published: 22 July 2025.
Edited and Reviewed by:
Pablo Engel, University of Barcelona, SpainCopyright © 2025 Silverman, Amarnani, Arbini, Kim, Kopinsky, Fenyo and Kister. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gregg J. Silverman, R3JlZ2cuU2lsdmVybWFuQG55dWxhbmdvbmUub3Jn